{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:26:56Z","timestamp":1785158816140,"version":"3.55.0"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>\n                    Hypereosinophilic syndromes (HES) comprise different clonal, reactive, or idiopathic\u00a0disorders characterized by elevated eosinophil levels and subsequent organ damage. Kim et\u00a0al. in a multicentre, single\u2010arm, prospective phase II study, treated 32 patients with\n                    <jats:italic>PDGFRA\/B<\/jats:italic>\n                    \u2010negative HES with imatinib at the dose of 100\u2013400\u2009mg daily. Respective overall and complete haematological response rates were 46.9% and 18.8%, and the median time to response was 1.5\u2009months. The molecular basis of responses was identified by using whole\u2010exome and whole\u2010transcriptome sequencing in 11 patients.\n                    <jats:italic>STAT5B::RARA<\/jats:italic>\n                    ,\n                    <jats:italic>PAK2::PIGX<\/jats:italic>\n                    , and\n                    <jats:italic>FIP1L1::CHIC2<\/jats:italic>\n                    fusions were identified in responders, whereas\n                    <jats:italic>RNF130::BRAF<\/jats:italic>\n                    and\n                    <jats:italic>WNK1::KDM5A<\/jats:italic>\n                    were identified in non\u2010responders. Imatinib could be a therapeutic option for some, possibly clonal,\n                    <jats:italic>PDGFRA\/B<\/jats:italic>\n                    \u2010negative HES.\n                  <\/jats:p>\n                  <jats:p>\n                    Commentary on: Kim et\u00a0al. Phase II trial of imatinib mesylate in patients with\n                    <jats:italic>PDGFRA\/B<\/jats:italic>\n                    \u2010negative hypereosinophilic syndrome. Br J Haematol 2024; 205:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/doi.org\/10.1111\/bjh.19828\">2305\u20102314<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1111\/bjh.19853","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T01:47:51Z","timestamp":1730166471000},"page":"2136-2138","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Imatinib is effective in some\n                    <i>PDGFRA\/B<\/i>\n                    \u2010negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms"],"prefix":"10.1111","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-1206","authenticated-orcid":false,"given":"Giuseppe G.","family":"Loscocco","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms Azienda Ospedaliero\u2010Universitaria Careggi, University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3703-1268","authenticated-orcid":false,"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Faculty of Medicine in Katowice Medical University of Silesia  Katowice Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26352"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19828"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025217"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.162"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-555607"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001111"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25945"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07893.x"},{"key":"e_1_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.10.004"},{"key":"e_1_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-9831-1"},{"key":"e_1_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12843"},{"key":"e_1_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.02.024"},{"key":"e_1_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000368"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19853","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.19853","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T22:11:21Z","timestamp":1771107081000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/bjh.19853"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19853","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"2024-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}